The First Psilocybin Clinics Will Probably Be Spravato Clinics
Virginia has already passed the law that would make an FDA-approved psilocybin drug legal in the state. A company preparing to deliver it has now said where the first treatments will happen. Axios Richmond reported that Journey Clinical plans to start at its existing Spravato sites. Compass Pathways, the drug’s developer, is planning the same thing nationally.
The clinics best positioned for psilocybin already carry a REMS certification and a monitoring room. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| The state law | Virginia HB 1347 and SB 379, signed April 13, 2026, reschedule psilocybin once FDA approves a formulation |
| The drug | Compass Pathways’ COMP360, for treatment-resistant depression, now in a rolling FDA application |
| Journey’s plan | Existing Spravato sites would offer COMP360 first, then expand |
| Compass’s plan | Collaborations with more than 1,000 sites that already deliver Spravato |
| The timeline claim | Launch in the first half of 2027, which is a company target and not an FDA date |
| The catch | DEA rescheduling and a state board vote both come after approval, adding months |
What Virginia Already Passed
Governor Abigail Spanberger signed HB 1347 and SB 379 on April 13, 2026. The bills direct the Virginia Board of Pharmacy to reschedule an FDA-approved psilocybin formulation to match federal scheduling.
It is a trigger law. It changes nothing today, and activates only if a psilocybin drug wins federal approval. Marijuana Moment reported the signing.
Sponsor Senator Jennifer Boysko has said the law covers clinical settings only. It does not decriminalize psilocybin and does not create recreational access.
Approval Is Not the Start Date
The sequence is longer than most coverage suggests. FDA approval comes first. Then the DEA has to change psilocybin’s federal classification.
Only after that can Virginia’s Board of Pharmacy act. After the board votes, the change generally takes three to four months to take effect, according to the state Department of Health Professions.
So a clinic planning around an approval date is planning around the wrong date. The practical start is DEA action plus a state rulemaking cycle.
Journey Clinical’s Plan
Journey Clinical works with Compass on how COMP360 could reach patients. It also offers Spravato at certified medical facilities, and partners with about 100 therapists in Virginia.
Co-founder and CEO Myriam Barthes told Axios the company has mapped the rollout. That covers patient eligibility, insurance approval and appointment logistics. If COMP360 is approved, its Spravato sites would be first in line.
Journey’s only Virginia Spravato site today is in Charlottesville. Executive Nora Studholme said Richmond is absolutely in the company’s expansion plans.
Compass Is Planning This at Scale
Journey is one partner, not the whole strategy. Compass has said it has strategic collaborations with more than 1,000 sites that currently deliver Spravato.
It has also pointed to more than 8,000 interventional psychiatry sites already running multi-hour treatments. Those include Spravato, TMS and ECT. Its commercial plan includes administration billing codes, a buy-and-bill model and training grants for providers.
Compass expects to finish its rolling application by the end of 2026. It targets a launch in the first half of 2027, subject to FDA, DEA and state action. We covered the company’s position in our look at likely psychedelic acquisition targets.
Why Spravato Sites Fit
COMP360 would not be a pharmacy prescription. Patients would be screened, dosed at a treatment site and monitored for several hours.
Spravato clinics already do a version of that. They hold REMS certification, run supervised administration with post-dose monitoring, and bill for it. That model has scaled into a business worth more than half a billion dollars a quarter.
The difference is duration. A Spravato visit requires two hours of monitoring. A psilocybin session runs far longer, and that changes chair economics. We laid it out in our piece on session length.
Read the Timeline Claims Carefully
Journey told Axios it expects approval by the end of the year and a rollout in early 2027. Axios noted that is Journey’s projection, not an FDA timeline.
Compass’s 2027 launch target is a company target too. Both firms have a commercial interest in projecting an early start.
Neither makes the plans less real. It does mean the dates should be read as intentions.
What It Means for Clinics
If you already run a Spravato program, you are the site this rollout is being designed around. The REMS workflow, monitoring space and prior authorization experience are the assets that matter.
If you do not, that gap is the thing to close first. The practices positioned for psilocybin are not the ones with the most ketamine experience. They are the ones with certified, billable, supervised administration.
State law matters too. Virginia has a trigger law in place. States without one will need a legislative cycle after federal approval. Others, such as New Mexico, are building separate programs entirely.
The Bottom Line
The first psilocybin clinics in America will probably be Spravato clinics. That is now the stated plan of the drug’s developer and at least one of its delivery partners.
Federal agencies are pointing states the same way, as SAMHSA’s recent guidance showed. FDA laid out its own approval thinking at its September public hearing.
Patients looking for supervised care can start with our directory of Spravato clinics near you.
This article is for informational purposes and is not legal or medical advice. Psilocybin is not FDA approved and remains a Schedule I substance under federal law.
